United States - English - NLM (National Library of Medicine)

roerig - penicillin g potassium (unii: vl775zth4c) (penicillin g - unii:q42t66vg0c) - penicillin g 5000000 [iu] - penicillin g potassium for injection, usp is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin g. therapy with penicillin g potassium for injection, usp may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis streptococcus pyogenes (group a β-hemolytic streptococcus), other β-hemolytic streptococci including groups c, h, g, l and m, streptococcus pneumoniae and staphylococcus species (non-penicillinase producing strains) anthrax bacillus anthracis actinomycosis (cervico-facial disease and thoracic and abdominal disease) actinomyces israelii botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) clostridium species diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) corynebacterium diphtheriae erysipelothrix endocarditis erysipelothrix rhusiopathiae fusospirochetosis (severe infections of the oropharynx [vincent's], lower respiratory tract and genital area) fusobacterium species and spirochetes listeria infections including meningitis and endocarditis listeria monocytogenes pasteurella infections including bacteremia and meningitis pasteurella multocida haverhill fever streptobacillus moniliformis rat bite fever spirillum minus or streptobacillus moniliformis disseminated gonococcal infections neisseria gonorrhoeae (penicillin-susceptible) syphilis (congenital and neurosyphilis) treponema pallidum meningococcal meningitis and/or septicemia neisseria meningitidis gram-negative bacillary infections (bacteremias) penicillin g is not the drug of choice in the treatment of gram-negative bacillary infections. gram-negative bacillary organisms (i.e . enterobacteriaceae) to reduce the development of drug-resistant bacteria and maintain effectiveness of penicillin g potassium and other antibacterial drugs, penicillin g potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. a history of a hypersensitivity (anaphylactic) reaction to any penicillin is a contraindication.

United States - English - NLM (National Library of Medicine)

roerig - penicillin g potassium (unii: vl775zth4c) (penicillin g - unii:q42t66vg0c) - penicillin g 5000000 [iu] - penicillin g potassium for injection, usp is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin g. therapy with penicillin g potassium for injection, usp may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis streptococcus pyogenes (group a β-hemolytic streptococcus), other β-hemolytic streptococci including groups c, h, g, l and m, streptococcus pneumoniae and staphylococcus species (non-penicillinase producing strains) anthrax bacillus anthracis actinomycosis (cervico-facial disease and thoracic and abdominal disease) actinomyces israelii botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) clostridium species diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) corynebacterium diphtheriae erysipelothrix endocarditis erysipelothrix rhusiopathiae fusospirochetosis (severe infections of the oropharynx [vincent's], lower respiratory tract and genital area) fusobacterium species and spirochetes listeria infections including meningitis and endocarditis listeria monocytogenes pasteurella infections including bacteremia and meningitis pasteurella multocida haverhill fever streptobacillus moniliformis rat bite fever spirillum minus or streptobacillus moniliformis disseminated gonococcal infections neisseria gonorrhoeae (penicillin-susceptible) syphilis (congenital and neurosyphilis) treponema pallidum meningococcal meningitis and/or septicemia neisseria meningitidis gram-negative bacillary infections (bacteremias) penicillin g is not the drug of choice in the treatment of gram-negative bacillary infections. gram-negative bacillary organisms (i.e . enterobacteriaceae) to reduce the development of drug-resistant bacteria and maintain effectiveness of penicillin g potassium and other antibacterial drugs, penicillin g potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. a history of a hypersensitivity (anaphylactic) reaction to any penicillin is a contraindication.

United States - English - NLM (National Library of Medicine)

athenex pharmaceutical division, llc. - penicillin g potassium (unii: vl775zth4c) (penicillin g - unii:q42t66vg0c) - penicillin g potassium for injection, usp is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin g. therapy with penicillin g potassium for injection, usp may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. to reduce the development of drug-resistant bacteria and maintain effectiveness of penicillin g potassium for injection, usp and other antibacterial drugs, penicillin g potassium for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. a history of a hypersensitivity (anaphylactic) reaction to any penicillin is a contraindication.

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - penicillin g potassium (unii: vl775zth4c) (penicillin g - unii:q42t66vg0c) - therapy buffered penicillin g potassium for injection, usp is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin g. therapy with buffered penicillin g potassium for injection, usp may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. to reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin g potassium and other antibacterial drugs, penicillin g potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility in

United States - English - NLM (National Library of Medicine)

professional complementary health formulas - pygeum africanum 2x sabal serrulata 2x bee pollen 3x zincum metallicum 3x prostate 6x pulsatilla 12x tuberculinum 30x, 100x - for the temporary relief of difficult urination, excessive or frequent urge to urinate, or mild discomfort in the groin or genitals.* *claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

Australia - English - Department of Health (Therapeutic Goods Administration)

siemens healthcare pty ltd - ct846 - prostate specific marker ivds - for in vitro diagnostic use in the determination of prostate specific markers in clinical specimens.

Australia - English - Department of Health (Therapeutic Goods Administration)

siemens healthcare pty ltd - ct846 - prostate specific marker ivds - for in vitro diagnostic use in the quantitative and/or qualitative determination of prostate specific markers in a clinical specimen. these measurements are used in conjunction with other diagnostic procedures to aid in patient management.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche diagnostics australia pty limited - ct846 - prostate specific marker ivds - the elecsys total and free psa immunoassays, are quantitative in vitro diagnostic tests for total (free + complexed) as well as free prostate-specific antigen in human serum and plasma, are indicated for the measurement of psa in conjunction with digital rectal examination (dre) as an aid in the detection of prostate cancer in men aged 50 years or older. prostate biopsy is required for diagnosis of prostate cancer. the tests are further indicated for serial measurement of psa to aid in the management of cancer patients. the electrochemiluminescence immunoassay ?eclia? is intended for use on elecsys and cobas e immunoassay analyzers. gmdns code and description: prostate specific marker ivds[ct846]

Australia - English - Department of Health (Therapeutic Goods Administration)

siemens healthcare pty ltd - ct846 - prostate specific marker ivds - for in vitro diagnostic use in the quantitative and/or qualitative determination of prostate specific markers in a clinical specimen.

Australia - English - Department of Health (Therapeutic Goods Administration)

ortho-clinical diagnostics australia pty ltd - ct846 - prostate specific marker ivds - ivds that are intended to be used for the qualitative and/or quantitative determination of prostate specific markers in a clinical specimen.